Drug-eluting stents: a new treatment in the prevention of restenosis Part II: clinical studies

References

• Vrolix MC, Legrand VM, Reiber JH, Grollier G, Schalij MJ, Brunel P, Martinez-Elbal L, Gomez-Recio M, Bar FIAT, Bertrand ME, Colombo A, Brachman J. Heparin-coated Wik-tor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol 2000; 86: 385–9.
   Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morei M-A. A comparison of balloon-expandable-stent implantation with balloon angio-plasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489–95.
   Google Scholar
• Van Langenhove G, Vermeersch P, Serrano P, Kutryk MJ, Stockman D, Convens C, Van den BF, Vanagt E, Albertal M, Van den HP. Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up. Can J Cardiol 2000; 16: 473–80.
   Google Scholar
• Shin EK, Son JW, Sohn MS, Jin DK, Park GS, Koh KK, Alm TH, Choi IS. Efficacy of heparin-coated stent in early setting of acute myocardial infarction. Catheter Cardiovasc Interv 2001; 52: 306–12.
   Google Scholar
• Savage MP, Douglas JS, Jr., Fischman DL, Pepine CJ, King SB, III, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg S. Stent placement com-pared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337: 740–7.
   Google Scholar
• Stone GW, Brodie BR, Griffin JJ, Costantini C, Morice MC, St Goar FG, Overlie PA, Popma JJ, McDonnell J, Jones D, O’Neill WW, Grines CL. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation 1999; 99: 1548–54.
   Google Scholar
• Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der GW, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuels-son H, Fajadet J, Haude M, Klugmann S, Morel MA. Ran-domised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coro-nary artery disease (Benestent II). Lancet 1998; 352: 673–81.
   Google Scholar
• Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, Anderson TJ, Knudtson ML, Marquis JF, Suzuki T, Cohen EA, Fox RS, Teo KK. Primary stenting versus balloon angioplasty in occluded coronary arteries. The Total Occlusion Study of Canada (TOSCA). Circulation 1999; 100: 236–42.
   Google Scholar
• Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Bmdie BR, Madonna 0, Eijgelshoven M, Lansky AJ, O’Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarc-tion Study Group. N Engl J Med 1999; 341: 1949–56.
   Google Scholar
• Moer R, Myreng Y, Molstad P, Albertsson P, Gunnes P, Lindvall B, Wiseth R, Ytre-Arne K, Kjekshus J, Golf S. Stent-ing in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol 2001; 38: 1598–603.
   Google Scholar
• Kastrati A, Schömig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann F-J. A randomized trial compar-ing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. Circula-tion 2000; 102: 2593–8.
   Google Scholar
• Muramatsu T, Tsukahara R, Ho M, Ito Y, Ishimori H, Hirano K, Nakano M, Matsushita M, Leung WY Clinical outcome of stent implantation in small coronary arteries using different types of coronary stents. J Invasive Cardiol 2001; 13: 634–9.
   Google Scholar
• Liu XS, Hanet C, Vandormael M, Legrand V, Huang YM, De Scheerder I. Study of anti-restenosis with the bIodivy-sio dexamethansone eluting stent (STRIDE) - a multicenter trial. Eur Heart J2002; 23 suppl.: 265.
   Google Scholar
• Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IMF, Seixas AC, Staico R, Mattos LA, Sousa AGMR, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neoin-timal proliferation after implantation of sirolimus-coated stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2000; 103: 192–5.
   Google Scholar
• Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sustained sup-pression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007–11.
   Google Scholar
• Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter PJ, Serruys PW. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001; 22: 2125–30.
   Google Scholar
• Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW. Two-year angiographic and intravas-cular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003; 107: 381–3.
   Google Scholar
• Sousa JE, Abizaid A, Abizaid A, Feres F, Maldonado G, Pinto I, Seixas AC, Tanajura LF, Sousa AGMR, Jaeger J, Popma J, Serruys PW. Late (three-year) follow-up from the first-in-man (FIM) experience after implantation of sirolimus-eluting stents. Circulation 2002; 106 suppl. II: 11–394.
   Google Scholar
• Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, Centemero M, Maldonado G, Abizaid AS, Pinto I, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sirolimus-eluting stent for the treatment of in-stent resteno-sis: a quantitative coronary angiography and three-dimen-sional intravascular ultrasound study. Circulation 2003; 107: 24–7.
   Google Scholar
• Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SG, De Feyter P, Vos J, Foley DP, Ligthart JM, Popma JJ, Serruys PW. Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clini-cal experience. J Am Coll Cardiol 2003; 41: 184–9.
   Google Scholar
• Honda Y, Grube E, de La Fuente LM, Yock PG, Stertzer SH, Fitzgerald PJ. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001; 104: 380–3.
   Google Scholar
• Sheppard R, Eisenberg MJ. Intracoronary radiotherapy for restenosis. N Eng J Med 2001; 344: 295–7.
   Google Scholar
• de La Fuente LM, Miano J, Mrad J, Penaloza E, Yeung AC, Eury R, Froix M, Fitzgerald PJ, Stertzer SH. Initial results of the Quanam drug eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects. Catheter Cardiovasc Interv 2001; 53: 480–8.
   Google Scholar
• Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, Moshiri S, Montorfano M, Carlino M, Briguori C, Pag-notta P, Albiero R, Corvaja N, Colombo A. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis. Immediate and long-term clinical and angiographic outcome. Circulation 2002; 105: 1883–6.
   Google Scholar
• Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002; 106: 2649–51.
   Google Scholar
• Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, De Feyter P, Muller R, Regar E, Degertekin M, Ligthart JMR, Disco C, Backx B, Russell ME. TAXUS III trial. In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559–64.
   Google Scholar
• Sousa JE, Abizaid A, Abizaid A S, New G, Costa MA, Staico R, Feres F, Sousa AGM. R, Mehran R, Kipshidze N, Goodhand M, Kreimer S, Moses J, Leon M. First clinical experience with 17-B estradiol-eluting biodivysiomatrix LO stent to prevent restenosis in de novo native coronary arter-ies. Early clinical outcomes and angiographic follow-up from the EASTER trial. Circulation 2002; 106 suppl. II: 11–393.
   Google Scholar
• Abizaid AA, New G, Abizaid AS, Costa M, Vaz V, Kip-shidze N, Staico R, Feres F, Mehran R, Pinto I, Roubin G, Iyer S, Moses J, Leon M, Sousa A, Sousa JEM. First clinical experience with 17-estradiol-eluting BiodivYsio matrix LO stent to prevent restenosis in de-novo native coronary arteries: six-month clinical outcomes and angiographic follow-up from the EASTER trial. J Am Coll Cardiol 2003; 41 suppl.A: 56A.
   Google Scholar
• Wöhrle J, Al-Khayer E, Grötzinger U, Schindler C, Kochs M, Hombach V, Höher M. Comparison of the heparin coated vs the uncoated Jostent—no influence on restenosis or clini-cal outcome. Eur Heart J2001; 22: 1808–16.
   Google Scholar
• Haude M, Konorza T, Kalnins U, Erglis A, Saunamäki K, Glogar D, Grube E, Gil R, Serra A, Richardt H, Sick P, Erbel R. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients (COAST trial). Circulation 2003; 107:1265–70.
   Google Scholar
• Haude M, Konorza T, Kalnins U, Erglis A, Saunamäki K, Glogar H, Muller R, Gil R, Serra A, Richardt HG, Sick P, Erbel R. Heparin-coated stents in patients with high risk for major adverse cardiac events: a subgroup analysis of the COAST trial. Circulation 2002; 106 suppl. II: 11–356.
   Google Scholar
• Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.
   Google Scholar
• Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC. Intravascular ultra-sound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002; 106: 798–803.
   Google Scholar
• Abizaid AS, Abizaid A, Seixas AC, Feres F, Tanajura LF, Mattos LA, Pinto I, Centemero M, Chaves A, Staico R, Sousa AGMR. Eighteen-month clinical, angiographic and IVUS follow-up of the RAVEL study: a single-center expe-rience with 47 patients. Circulation 2002; 106 suppl. II: II–519.
   Google Scholar
• Tanabe K, Serruys PW, Degertekin M, Regar E, van Dom-burg RT, Sousa JE, Wulfert E, Morice MC. Fate of side branches after coronary arterial sirolimus-eluting stent implantation. Am J Cardiol 2002; 90: 937–41.
   Google Scholar
• Leon MB, Moses JW, Popma JJ, Fishell T, Wong SC, Midei M, Douglas J, Lambert C, Mooney M, Teirstein P, Kuntz R. A multicenter randomized clinical sltudy of the sirolimus-eluting stent in native coronary lesions: angio-graphic results. Circulation 2002; 106 suppl. II: 11–393.
   Google Scholar
• Popma JJ, Cox NR, Moses JW, Teirstein PS, Leon MB, Kuntz RE. Effect of vessel size on angiographic restenosis in a randomized comparison of bare metal and sirolimus-eluting Bx velocity stents: a SIRIUS trial substudy. Circula-tion 2002; 106 suppl. II: 11–520.
   Google Scholar
• Weisz G, Dangas G, Colombo A, Moussa I, Collins M, Adamian M, Adamyan Y, Ashby D, LaRoche V, Lansky A, Mehran R, Teirstein P, Stone GW, Moses JW, Leon MB. T-Stenting technique with sirolimus-eluting stents for bifur-cation lesions. Am J Cardiol 2002; 90 suppl. 6A: 5H
   Google Scholar
• Moses JW, Leon MB, Popma JJ, Caputo R, O’ShaughnessyC, Brown C, Kereiakas D, Williams DO, Teirstein PS, Kuntz RE. A multicenter randomised clinical study of the sirolimus-eluting stent in native coronary lesions: clinical outcomes. Circulation 2002; 106 suppl. II: 11–392.
   Google Scholar
• MorinoY, Ako J, Sonoda S, Terashima M, Hassan AHM, Jaeger JL, Reisman M, Wong SC, Bass TA, Honda Y, Fitzgerald PJ. Neointimal distribution within sirolimus-eluting stents: a 3-D IVUS interim analysis from the SIR-IUS trial. Circulation 2002; 106 suppl. II: 11–391.
   Google Scholar
• Cox NR, Popma JJ, Prpic R, Cutlip D, Kuntz R, Moses JW, Leon MB. Does “geographic miss” account for peri-stent restenosis in patients undergoing sirolimus-eluting Bx veloc-ity stent implantation? Circulation 2002; 106 suppl. II: II–519.
   Google Scholar
• Ako J, Morino Y, Honda Y, Sonoda S, Terashima M, Jaeger JL, Palacios IF, Brown C L, Baim DS, Fitzgerald PJ. Inci-dence of incomplete stent apposition at baseline and follow-up: interim analysis from the SIRIUS trial. Circulation 2002; 106 suppl. II: 11–520.
   Google Scholar
• Schofer J. Results of the E-SIRIUS-trial: a European multi-centre, randomised, double-blind study of the sirolimus-eluting stent in patients with de novo coronary artery lesions. Proceedings of the ACC Conference; 2003 Mar 30-Apr 3; Chicago.
   Google Scholar
• Park S-J, Shim WH, Ho DS, Raizner AE, Park S-W, Hong M-K, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537–45.
   Google Scholar
• Hong M-K, Mintz GS, Lee CW, Song J-M, Han K-H, Kang D-H, Song J-K, Kim J-J, Weissman NJ, Fearnot NE, Park S-W, Park S-J. Paclitaxel coating reduces in-stent inti-mal hyperplasia in human coronary arteries. A serial volu-metric intravascular ultrasound analysis from the Asian paclitaxel-eluting stent clinical trial (ASPECT). Circulation 2003; 107: 517–20.
   Google Scholar
• Park S, ShimWH., HoD, Raizner AE. Long-term follow-up in the ASPECT clinical study. Am J Cardiol 2002; 90 suppl. 6A: 1H.
   Google Scholar
• Gershlick AH, De Scheerder I, Chevalier B, Camenzind E, Gommeaux A, Vrints C, Reifart N, Missault L, Goy J-J, Brinker JA, Stephens-Lloyd A, Heldman AW. Local drug delivery to inhibit coronary artery restenosis. Data from the ELUTES (EvaLUation of pacliTaxel Eluting Stent) clinical trial. Circulation 2001; 104 suppl. II: 11–416.
   Google Scholar
• Gershlick A, De Scheerder I, Chevalier B. Long-term follow-up in the ELUTES clinical study. Am J Cardiol 2002; 90 suppl. 6A: 1H.
   Google Scholar
• Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38–42.
   Google Scholar
• Knopf W, O’Neill W, Midei M, Cox D, O’Shaughnessy C, Applegate R, Cannon L, Mooney M, Farah A, Sharon 0, Toyloy S, Linnemeier T. The DELIVER clinical trial: 30-day safety data from a multicenter, randomized clinical eval-uation of the ACHIEVE drug-eluting coronary stent sys-tem. Am J Cardiol 2002; 90 suppl. 6A: 70H.
   Google Scholar
• Grube E, Lansky AJ, Reifart N, Fajadet J, DiSciascio G, Dimario C, Hauptmann K, Colombo A, Bach R, Silber, S. SCORE Six-month angiographic results: improved resteno-sis in patients receiving the QUADDS-QP2 drug-eluting stent compared with the control, bare stents. J Am Coll Car-diol 2002; 39 suppl. A: 38A.
   Google Scholar
• Grube E, Hauptmann K, Colombo A, DiSciascio G, Sil-ber S, Bach R, Dimario C, Reifart N, Fajadet J. SCORE Trial interim safety results: despite efficacy, late stent throm-bosis with the QuaDDS-5P2 stent. J Am Coll Cardiol 2002; 39 suppl. A, 59A.
   Google Scholar
• Chevalier B, De Scheerder I. First in man safety study of batimastat stent: effect on restenosis. Circulation 2002; 106 suppl. II: 11–520.
   Google Scholar
• Gerckens U, Buellesfeld L, Horstkotte D, Mueller R, Staberock M, Selbach G, Schmidt, T, Grube E. Evaluation of a tracrolimus-eluting coronary stent with nanoporous ceramic coating in treatment of native coronary artery lesions: phase I and II of the PRESENT study. J Am Coll Cardiol 2003; 41 suppl. A: 7A.
   Google Scholar
• Grube E, Gerckens U, Buelleslfeld L, Bootsveld A, Techen G, Staberock M, Selbach G, Mueller R. First human experi-ence using a new everolimus stent coating: early findings of the FUTURE trial. Am J Cardiol 2002; 90 suppl. 6A: 71H.
   Google Scholar
• Abizaid A, Ormiston J, Sousa JE, Feres F, Staico R, Seixas AC, Ruygrok P, Webster M, Stewart J, Morrison L. First in man experience with mycophenolic acid-eluting duraflex stent to treat de novo native coronary stenosis: early results from the IMPACT trial. Circulation 2002; 106 suppl. II: 11–357.
   Google Scholar
• Ellis SG, Hermiller JB, Cox DA, Turco MA, Caputo RP, Mann JT, Kutcher MA, O’Shaughnessy CS, Greenberg JD, Russell ME, Stone GW. The U.S. pivotal randomized trial of a polymer-based slow-rate release paclitaxel eluting stent: 30-day results of TAXUS-IV SR. Circulation 2002; 106 suppl. II: 11–393.
   Google Scholar
• Grube E, Bartorelli A, Blanchard D, Gershlick AT, Macaya C, Wijns W, Henry S, Homsy C. Evaluation of the ACHIEVE drug-eluting stent in complex lesions: the DELIVER II study. Am J Cardiol 2002; 90 suppl. 6A: 74H.
   Google Scholar
• De Scheerder I. The in-stent ELUTES study: a prospective, randomized, controlled, multicenter study to evaluate the V-flex plus PTX drug-eluting coronary stent to treat in-stent restenosis. Am J Cardiol 2002; 90 suppl. 6A: 71H.
   Google Scholar
• Kwok OH, Chow WH, Lee CH, Law TC, Chiu A, Popma JJ. First human experience with angiopeptin-eluting stent: preliminary clinical outcome of the stent with angiopeptin (SWAN) trial. Am J Cardiol 2002; 90 suppl. 6A: 72H.
   Google Scholar
• Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473–9.
   Google Scholar
• Liistro F, Colombo A. Late acute thrombosis after pacli-taxel eluting stent implantation. Heart 2001; 86: 262–4.
   Google Scholar
• Aggarwal M, Tsao PS, Kopia G, Yeung A, Tio F, Falotico R, Carter, AJ. Stent based delivery of sirolimus is associated with increased levels of p27kiP1 without long-term suppres-sion of neointimal hyperplasia in the porcine model. Circu-lation 2002; 106 suppl. II: 11–357.
   Google Scholar
• Kay IP, Wardeh AJ, Kozuma K, Foley DP, Knook AHM, Thury A, Sianos G, van der Giessen WJ, Levendag PC, Serruys PW. Radioactive stents delay but do not prevent in-stent neointimal hyperplasia. Circulation 2001; 103: 14–7.
   Google Scholar
• Vetrovec GW, Rizik D, Goudreau E, Cowley M, Malloy W, Lipinski M, Fernandez C, Piotrovskij V, Lonzetta L, Kopia G, Helbig J, Drum D. The sirolimus PK trial: a phar-macologic study of the sirolimus-eluting BX velocity stent in patients with de novo coronary lesions. Circulation 2002; 106 suppl. II: 11–355.
   Google Scholar
• Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Cir-culation 2001; 104: 600–5.
   Google Scholar
• Hwang CW, Edelman ER. Arterial ultrastructure influences transport of locally delivered drugs. Circ Res 2002; 90: 826–32.
   Google Scholar